4basebio Plc · LSE:4BB
4basebio — Investor Presentation (January 2021)
18 slides from 4basebio's investor presentation, January 2021
Slide 1: Next Generation Gene Therapy
NEXT GENERATION GENE THERAPY Innovation in gene synthesis & delivery January 2021
Slide 2: Disclaimer
Disclaimer This document is intended for shareholders, prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estim
Slide 3: 4basebio UK Societas (4basebio)
4basebio UK Societas (4basebio) • Headquartered near Cambridge, UK 4basebio UK Societas • Spin out from 4basebio AG (listed on the Frankfurt Stock Market) 4basebio UK 4basebio SLU • Focussed on development of next generation synthetic Limited DNA and the development of non-viral delivery systems, wi
Slide 4: Origins of 4basebio UK Societas (4basebio)
Origins of 4basebio UK Societas (4basebio) • Originally a 2019 incorporated German European 4basebio SE stock corporation which changed its registered office to the UK in December 2020 4basebio UK Societas • Became UK Societas following Brexit 4basebio PLC • Plan to convert to 4basebio PLC following
Slide 5: Background to spin out
Background to spin out 4basebio AG (formerly €120m Abcam Expedeon AG) genomics proteomics immunology 4basebio UK Societas €16m cash €25m debt facility Corporate Presentation 5
Slide 6: 4basebio UK Societas (4basebio)
4basebio UK Societas (4basebio) • Admission to AIM 4basebio UK • 4basebio is a UK / Spanish company: Societas • 12 staff in Cambridge; 12 staff in Madrid • including 18 scientists • Spain: Early stage R&D and enzyme manufacture 4basebio UK 4basebio SLU • UK: DNA commercialisation and nanoparticle Li
Slide 7: Business Focus
Business Focus Developing – 1. next generation synthetic DNA 2. non-viral delivery systems 4basebio SLU • Expertise in DNA enzymology • Intellectual property in DNA synthesis • Developed next-gen. synthetic DNA Synthetic DNA • Extremely suitable for gene therapies • Gene therapies require a lot of D
Slide 8: Synthetic DNA
Synthetic DNA Proprietary Trueprime® technology; Current market practice – enables production of large quantities of synthetic hpDNATM Biofermentation: plasmid DNA 1. quick large scale bioreactors 2. cost effective 4basebio DNA 3. safe complex DNA purification Corporate Presentation 8
Slide 9: hpDNA near term objectives
hpDNA™ near term objectives • Development milestones 1. Scale manufacturing to commercial levels 2. Demonstrate DNA comparable with plasmid DNA 3. Produce GMP grade DNA • Validation through combination of: 1. In house development 2. External partnering arrangements Corporate Presentation 9
Slide 10: Market opportunity
Market opportunity The regenerative medicine sector is rapidly 1066 clinical trials in the field of regenerative growing medicine/advanced therapies • In 2019, nearly a hundred Phase 3 trials have been 500 active 450 • Several late-stage products are awaiting approval and 400 following commercializa
Slide 11: Business Focus
Business Focus Developing – 1. next generation synthetic DNA Gene delivery systems 2. non-viral delivery systems Non-viral Viral Non- Non- Integrating Integrating integrating integrating Nanoparticles Transposons, AAV, Adeno, Lentivirus, Crispr/Cas9, gene hpDNA HSV-1, Baculovirus Retrovirus editing
Slide 12: Commercial summary
Commercial summary 1. Manufacture synthetic DNA, i.e. hpDNA™, for sale to third parties 2. Develop and manufacture non-viral delivery systems, i.e. Hermes™ nanoparticles, for sale or licensing to third parties 3. Identify a number of indications for which we can progress potential gene therapies thr
Slide 13: 4basebio technology focus - summary
4basebio technology focus - summary synthetic DNA non-viral nanoparticles • Next generation technology covered by IP • Developing non-viral delivery systems • Very clear advantages over plasmid DNA: • Addressing therapies outside the scope and • Safety: no endotoxins, no bacterial DNA capabilities o
Slide 14: Shareholder value
Shareholder value 1. Develop a valuable technology portfolio 2. Build a strongly profitable life sciences company Recent transactions in this space: Corporate Presentation 14
Slide 15: Management of 4basebio UK Societas
Management of 4basebio UK Societas Non-Executive Directors Executive Directors Tim McCarthy Heikki Lanckriet David Roth Chairman CEO, CSO CFO Pilar de la Huerta Hansjörg Plaggemars Joseph Pilar deFernandez la Huerta Corporate Presentation 15
Slide 16: Shareholder Structure
Shareholder Structure 1. Company free float is about 34% Free float, 34.0% 4basebio AG, 2. A 30% stake is retained by the former 30.0% parent 4basebio AG 3. Deutsche Balaton, a significant investor in Heikki Lanckriet, CEO, 10.0% 4basebio AG has a stake of 20% through the spin out David Roth, CFO, 2
Slide 17: Financial expectations and near term objectives
Financial expectations and near term objectives 4basebio is well financed Nanoparticles – Create delivery system IP; identify gene therapy candidates • ~€16m/£14.4m day one cash; €25m/£22m loan facility with 4basebio AG • Partnering with research groups, gene therapy and DNA vaccine developers to de
Slide 18: Summary
Summary 4basebio is: well funded to take advantage of the growing gene therapy market : • Next generation synthetic DNA • Non-viral nanoparticle delivery systems potential to create significant shareholder value through: • Manufacture and sale of hpDNA • Licensing and sale of Hermes nanoparticles •